Nexen

Quick links to important sections

Nexen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nexen

Property Description
Active Ingredient Nimesulide
Form Tablet, Granules for oral suspension, Topical gel
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General Purpose Relieves pain, inflammation, and fever
Origin Synthetic compound (Sulfonanilide)

Defining Nexen: A Selective Non-Steroidal Anti-Inflammatory Drug

Nexen is a medicine classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), used for its core capacity to mitigate pain, inflammation, and fever. The active component is the substance Nimesulide, which is chemically a synthetic sulfonanilide. This compound is distinctive because it operates as a preferential or selective inhibitor of the Cyclooxygenase-2 (COX-2) isoenzyme. Nimesulide is classified as an NSAID used for managing acute physical symptoms.

Active Ingredient, Composition, and Available Forms

The medicine is supplied as a single-active-ingredient product, containing only Nimesulide (N-(4-nitro-2-phenoxyphenyl)methanesulfonamide). Nexen is differentiated in the market by providing a flexible range of dosage forms suited for either systemic or local administration, including tablets and granules for oral suspension for oral use, and a topical gel which utilizes a hydrogel base. NSAIDs like Nimesulide are available in both oral and topical preparations. The availability of the oral suspension granules, for instance, provides an alternative for patients who may have difficulty swallowing solid tablets.

The General Therapeutic Purpose of Nexen

The primary purpose of Nexen is to provide simultaneous relief from three core physiological symptoms: pain (analgesic effect), inflammation (anti-inflammatory effect), and fever (antipyretic effect). This comprehensive benefit is achieved because the selective inhibition of COX-2 calms the biochemical pathways responsible for generating the chemical mediators of these acute symptoms. The medicine is recognized for its role in managing the complex symptom constellation linked to inflammatory conditions, such as acute musculoskeletal pain or post-operative discomfort.

What side effects are possible with Nexen?

Possible Side Effects and Safety Information

This section summarizes the officially documented side effects and safety restrictions for Nexen (nimesulide), as specified in government regulatory documents from agencies such as the European Medicines Agency (EMA).

Safety Profile Overview

The primary safety concerns for Nexen revolve around serious effects on the hepatic (liver) and renal (kidney) systems, which have prompted significant regulatory restrictions on its use.

Regulatory actions, including a European reassessment, have established limitations to mitigate these documented risks, formalizing the drug's safety structure around its potential for severe adverse reactions.

Documented Adverse Reactions and Safety Limitations

Serious Adverse Reactions

Official regulatory sources have highlighted the potential for serious hepatic adverse effects, including cases of fulminant hepatitis and jaundice. Gastrointestinal adverse effects and impacts on renal function have also been identified.

Regulatory Limitations and Contraindications

The following are formal restrictions and contraindications based on the drug’s official safety profile:

  • Treatment Duration: Use is limited to a maximum of 15 days to minimize the risk of serious side effects.
  • Dosing Restriction: The maximum oral dose is reduced to 100 mg twice a day.
  • Contraindications: The medicine is formally contraindicated in patients with:
    • Severe renal impairment (creatinine clearance < 30 ml/min).
    • Hepatic impairment.
    • A known hypersensitivity to the drug substance or a history of hypersensitivity reactions to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs).

System-Organ Classes Involved

The primary system-organ classes of concern, as identified in regulatory reviews, include the Hepatic system, the Renal system, and the Gastrointestinal system. The decision to prescribe this medicine is formally required to be based on an assessment of these documented risks.

Overdose and Emergency Response

The official regulatory profile for Nimesulide overdose, documented in prescribing information, outlines a spectrum of clinical manifestations. Symptoms following an acute ingestion of large quantities are usually limited to effects such as nausea, vomiting, epigastric pain, lethargy, and drowsiness. Overdose resulting from the use of the topical gel formulation is not expected due to very low systemic absorption.

Despite the presentation of these generally limited initial symptoms, immediate medical attention is required due to the documented potential for rare, severe, or life-threatening outcomes. These serious manifestations may affect several physiological systems, including acute renal failure, respiratory depression, hypertension, severe gastrointestinal bleeding, and coma.

Management of a suspected overdose must focus strictly on providing symptomatic and supportive care. The regulatory guidance explicitly states that no specific antidotes are known for Nimesulide toxicity. Procedural steps such as gastric lavage or administration of activated charcoal may be considered by medical professionals. Continuous monitoring of both renal function and hepatic function is mandated. Procedures like forced diuresis or haemodialysis are noted to be likely ineffective for enhanced elimination due to the drug's high protein-binding characteristic.

Therapeutic Uses of Nexen

Nexen (Nimesulide) is used across several therapeutic domains for its role in managing symptoms of pain, inflammation, and fever. It is relevant in clinical settings marked by heightened patient distress and short-term, acute symptom manifestations. The core therapeutic utility is considered relevant for specific, acute conditions.

The medication is commonly used when short-term symptomatic assistance is needed for acute pain syndromes, relevant in contexts involving temporary discomfort following minor surgical or dental procedures, soft tissue injuries, and managing the painful symptoms of osteoarthritis during acute flares. It is also applied to ease the pronounced pain and cramping associated with primary dysmenorrhoea (menstrual pain). Its use helps address symptom clusters that may appear suddenly, supporting the patient during difficult episodes.

“The medication's symptomatic application is relevant for easing distress during difficult episodes.”

In situations where patients experience symptoms related to systemic imbalance, such as fever often accompanying acute inflammatory states, Nexen is applied in addressing elevated body temperature. By offering supportive therapeutic benefit for fever, it can contribute to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Symptomatic support in Acute Musculoskeletal Pain


Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Official Eligibility Constraints for Nexen (Nimesulide)

The use of Nexen is governed by strict regulatory rules that define the eligible population. The medicine is primarily intended for use as a second-line treatment for adults and adolescents from 12 years of age who are free of contraindications, with treatment strictly limited to a maximum duration of 15 consecutive days.

Absolute Contraindications

Nexen is prohibited for patients with any degree of hepatic impairment (liver disease) or a history of Nimesulide-related hepatotoxic reactions. It is also contraindicated in those with active gastrointestinal ulceration, severe heart failure, severe renal impairment (Creatinine Clearance < 30 ml/min), or severe coagulation disorders.

Age and Life Stage Exclusions

Use is contraindicated in children under 12 years of age. For women, the medicine is contraindicated during the third trimester of pregnancy and while breastfeeding. It is also not recommended for women attempting to conceive or during the first two trimesters of pregnancy. Additionally, use is prohibited in patients presenting with fever or flu-like symptoms.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information identifies specific categories of medicines that require caution or procedural changes when used alongside Nexen (cefuroxime). This is to manage the risk of altered medicine effectiveness or potential for increased effects on the body.

Documented Interaction Categories

Interacting Product Category Official Constraint/Requirement
Oral Contraceptives May cause failure of contraceptive pills; require use of another method of contraception (e.g., condoms).
Anticoagulants (Blood thinners, e.g., Warfarin) Use with caution; may increase blood-thinning effect, necessitating close monitoring.
Uricosuric Agents (e.g., Probenecid) Use with caution; may increase the body's exposure to cefuroxime.
Medicines Reducing Gastric Acidity May lower the amount of cefuroxime absorbed by the body.

Concomitant use with oral contraceptive pills is officially documented as potentially reducing contraceptive effectiveness, mandating the use of supplementary birth control throughout treatment. The co-prescription of medicines such as Warfarin or Probenecid requires increased caution and monitoring due to the potential for significant increases in drug effects or exposure. Additionally, drugs that reduce stomach acid are noted as potentially lowering the bioavailability of this medicine. The official interaction profile directs that special monitoring or procedural changes are required, rather than prohibiting use, for these combinations.

Mechanism of Action

Preferential COX-2 Inhibition and Prostaglandin Modulation

The drug primarily works by acting as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme, which minimizes the production of pro-inflammatory Prostaglandin E2 ( PG E2). This molecular action reduces the sensitization of peripheral nociceptors in peripheral tissues and centrally in the hypothalamus, a step that resets the hypothalamic core temperature set-point.


Non- COX Cellular Protection and Anti-Catabolic Action

Beyond its primary enzyme target, the drug engages secondary mechanisms that contribute to its overall physiological effect. It acts as a scavenger of Reactive Oxygen Species ( ROS) (free radicals) and functions as an inhibitor of enzymes like Matrix Metalloproteinases ( MMPs) and the neutrophil oxidative burst. This activity attenuates the destructive activity of inflammatory cells and modulates the catabolism of structural tissues by inhibiting key enzymes.

Dosage and Administration Information

How to Use Nexen — Official Administration Guidelines

The usage of Nexen (Nimesulide) is defined by the posology across its systemic and topical forms. Administration is structured around a fixed dosing schedule for the shortest duration necessary.


Administration Scope

Feature Instruction
Route of administration Oral (for systemic effects) and Topical (for local application).
Dosing schedule Standard systemic dose is 100 mg per dose. The maximum systemic daily intake must not exceed 200 mg.
Timing in relation to meals Oral forms must be taken specifically after meals (post-prandial administration).
Age-group administration rules The standard adult dose is used for adolescents over 12 years of age. Use is not recommended for children under 12 years of age.
Special procedural conditions The systemic use of this medicine is restricted to a second-line treatment option.

Instruction Classifications (High-Level)

Classification Pattern
Administration method type Oral / Topical
Frequency pattern Twice daily (b.i.d.) for systemic use.
Use-context constraints Treatment course must utilize the minimum effective dose for the shortest possible duration.

Resulting Procedural Structure

Official step sequence:

  • The systemic dose is fixed at 100 mg and is taken post-prandially.
  • This dose is repeated twice daily (b.i.d.).
  • The maximum duration of any single systemic treatment course must not exceed 15 days.

Connection to the overall use protocol

These instructions establish a precise and time-limited administration protocol. The rule of 100 mg taken twice daily after food, combined with the 15-day maximum duration, defines the medicine as a short-term, acute systemic therapy. This framework ensures that the procedural steps for use are followed as established for this therapeutic class.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nexen (Nimesulide)

This section outlines how regulatory and scientific evidence for Nexen is structured, focusing on the types of studies conducted, the conditions they examined, and documented research limitations.


Evidence for Use in Acute Pain and Postoperative Settings

Research exploring Nexen was studied for its potential role in addressing outcomes related to physical discomfort, focusing primarily on short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time in adults and adolescents experiencing acute general pain or pain following minor surgery. The studies monitored patient-reported outcomes describing perceived discomfort, including measurements of the change in pain intensity and the total pain relief reported over the initial hours and days.

What remains uncertain is the long-term context of these findings. Evidence is explicitly limited to short-term treatment durations, typically up to 15 days, which aligns with regulatory expectations for acute symptomatic relief. There is limited information for long-term outcomes or the durability of the reported changes beyond the initial period of high symptom activity.


Evidence for Use in Primary Dysmenorrhoea and Inflammatory Conditions

For the management of menstrual pain (primary dysmenorrhoea), research explored the medicine through controlled clinical trials relevant in trials assessing short-term or episodic symptom patterns. These studies focused on conditions characterized by fluctuating manifestations, monitoring changes in reported pain severity over the course of a woman's menstrual cycle.

Nexen was also studied for its potential role in managing conditions associated with acute or disruptive episodes, such as painful osteoarthritis (OA) flares and localized soft tissue injuries (e.g., sprains). The evidence for the topical gel applies only to its local use and short-term observation of changes in localized pain and swelling. For systemic use in painful OA, evidence is limited because regulatory bodies have restricted its prescription due to risk-benefit concerns over extended periods, meaning data supporting chronic maintenance treatment for OA is actively limited.


Key Evidence Gaps and Remaining Uncertainty

The most significant limitation is the absence of comprehensive long-term evidence. Findings describe group patterns related to symptom patterns monitored during the acute study period, but follow-up durations were limited across the board, leaving long-term effects not fully established. Additionally, due to safety findings, evidence for use in children (pediatric populations) is now highly limited or restricted in many regions.

Key Studies & References

  1. Nimesulide in the treatment of osteoarthritis. Double-blind studies in comparison with piroxicam, ketoprofen and placebo (RCT for short-term OA)
  2. Nimesulide in dysmenorrhoea (Review on mechanism and clinical trials for menstrual pain)
  3. GLOBAL BAN ON NIMESULIDE: PHARMACOLOGICAL INSIGHS, SAFETY CORNERS, AND REGULATORY PRESPECIVE (Regulatory history and pediatric restrictions)

Frequently Asked Questions (FAQ)

Common questions about Nexen (FAQ)


Q: What is Nexen actually used for besides the main condition?

A: According to official regulatory documents, approved uses for this medicine include the treatment of acute pain, symptomatic pain associated with osteoarthritis, and relief of primary dysmenorrhoea (painful menstrual periods).


Q: Is Nexen an opioid or a steroid?

A: Nexen (Nimesulide) is not an opioid or a steroid. It is officially classified as a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID).


Q: Why do doctors prescribe Nexen instead of other similar medicines?

A: Official regulatory bodies have designated this medicine as a second-line treatment option. This means that its use is typically reserved for cases where patients have not responded adequately to other initial medications, based on an assessment of its established risk-benefit profile.


Q: How quickly can I expect Nexen to start working?

A: Official pharmacological information indicates that the drug has a fast onset of action after it is taken.


Q: What happens if I miss a dose of Nexen?

A: If a dose is forgotten, regulatory guidelines state that it should be taken as soon as the person remembers. However, if it is nearly time for the next scheduled dose, regulatory guidance suggests skipping the missed dose and advises against taking a double dose to compensate.


Q: Is it common to feel tired when first starting Nexen?

A: Official documentation lists drowsiness (somnolence) and fatigue as central nervous system side effects that have been reported by users.


Q: Can Nexen cause weight gain or loss?

A: Official side effect profiles indicate that the medicine may lead to fluid retention, which can cause edema and weight gain. Weight loss is not commonly cited as a direct side effect.


Q: Are headaches a frequent side effect of Nexen?

A: Headache is listed among the possible central nervous system side effects in the official undesirable effects section of the drug label.


Q: What are the most serious side effects I should watch out for with Nexen?

A: Official regulatory warnings highlight the risk of severe hepatic (liver) reactions, which can be serious. Other major risks include gastrointestinal bleeding, ulceration, or perforation.


Q: Does Nexen interact with common over-the-counter pain relievers?

A: Official documents strongly advise that using this medicine at the same time as other NSAIDs (including common over-the-counter pain relievers) should be avoided. This is because combining them may significantly increase the risk of gastrointestinal and bleeding complications.


Q: Is it safe to take Nexen with supplements like vitamins or herbal remedies?

A: Official regulatory guidance highlights these potential risks, particularly with herbal products known to affect the liver. Official guidance suggests awareness of these risks when combining the medicine with any other products.


Q: Can people with high blood pressure take Nexen?

A: Patients with uncontrolled hypertension (high blood pressure) should only be treated with this medicine after careful consideration by a prescriber. Official safety guidelines indicate the need for caution, as the drug may increase the risk of heart-related events.


Q: What does the official patient information say about taking Nexen during pregnancy?

A: According to official regulatory documents, the medicine is contraindicated, meaning it must not be used, during the last trimester of pregnancy. It is also generally not advised for use throughout pregnancy or while breastfeeding.


Q: Can Nexen be used by someone who has kidney problems?

A: Use of this medicine is contraindicated in patients with severe renal (kidney) impairment (defined as creatinine clearance less than 30 ml/min). For patients with mild-to-moderate impairment, use requires careful assessment.


Q: Is Nexen safe for older adults (seniors) to use?

A: Official information advises caution when the medicine is used in older adults because of a potentially higher risk of side effects. For those with only mild-to-moderate kidney issues, regulatory documents indicate that a dosage adjustment is generally not necessary for older patients with only mild-to-moderate kidney impairment.


Q: Is Nexen known to be habit-forming or addictive?

A: As an NSAID, the medicine is not classified as an opioid or a controlled substance. Official product information does not list addiction or habit formation as a clinical concern associated with this NSAID.


Q: Are the initial side effects of Nexen temporary?

A: Official documents note that serious adverse events, particularly those affecting the liver, have been reported to occur more frequently within the first few weeks of treatment.


Q: Does Nexen require any special lab tests while I am taking it?

A: Due to the official warning regarding liver risk, regulatory guidelines indicate the potential need for regular monitoring of liver function for patients using this medicine. Monitoring of kidney and heart function may also be considered in certain populations.


Q: Can Nexen be taken by someone with a history of heart issues?

A: The medicine is contraindicated in patients with a history of severe heart failure or those who have recently undergone coronary bypass surgery. For patients with other established heart conditions, its use requires careful consideration and risk assessment.


Q: What happens if I accidentally take two doses of Nexen?

A: Official information on overdose suggests that symptoms may include severe stomach pain, vomiting, drowsiness, dizziness, or difficulty breathing. If an overdose is suspected, official documents recommend seeking immediate medical attention or contacting a healthcare professional.


Q: Does Nexen affect your driving ability or ability to concentrate?

A: Official product information suggests that individuals who experience side effects such as dizziness, vertigo, or somnolence (drowsiness) should avoid driving or operating machinery.


Q: Does Nexen interact with alcohol?

A: Official regulatory guidelines indicate that use of this medicine with alcohol should be avoided. This is because alcohol is a liver-toxic agent, and combining it with the drug may increase the risk of liver injury.


Q: Is Nexen similar to an NSAID?

A: Yes, the medicine is officially classified as a non-steroidal anti-inflammatory drug (NSAID). It works by acting as a preferential inhibitor of the COX-2 enzyme in the body.


Q: How does the drug approval agency classify the safety profile of Nexen?

A: Regulatory agencies assessed the risk-benefit profile and designated the drug as a second-line treatment option. This classification, along with the strict 15-day maximum duration rule, is due to the potential risk of serious liver toxicity.


Q: Are there any specific warnings about Nexen mentioned in official drug labels?

A: Major warnings cited in official labels include the risk of serious hepatic reactions (liver damage), the potential for gastrointestinal bleeding, and the need for caution in patients with pre-existing heart conditions or uncontrolled high blood pressure.


Q: Do I need a special prescription or monitoring to get Nexen?

A: In most regions where it is approved, the medicine is available by prescription only. Due to safety concerns, official guidance mandates that its use is subject to regular monitoring of liver function.


Q: Will taking Nexen affect my sleep schedule?

A: Somnolence (drowsiness) is listed in the official documents as a possible side effect. This undesirable effect may potentially impact a person's sleep schedule.


Q: What should I do if a specific side effect is not listed on the packaging?

A: Official patient safety guidance advises that if any noticeable or severe symptoms are experienced, the patient should discontinue the medicine and seek advice from a healthcare professional.


Q: What is the main ingredient in Nexen?

A: The main active ingredient in the medicine, as identified in official product information, is nimesulide.


Q: Is Nexen available in different forms (e.g., liquid, tablet)?

A: Official product information states that the medicine is supplied in various forms. These include forms for systemic use (taken internally) and forms for local application (topical).


Q: Can Nexen cause stomach upset or digestive issues?

A: Yes, official documents state that gastrointestinal discomfort is a common side effect. This may include symptoms such as nausea, vomiting, diarrhea, or stomach pain.


Q: Are there different strengths of Nexen, and why would one be chosen over another?

A: The most common systemic strength is the 100 mg tablet, though other strengths may be available in some regions. The choice of specific strength and form is determined by a healthcare professional based on the condition being treated and the official administration guidelines.


Q: Does Nexen interact with medications for mental health conditions?

A: Official drug interaction data indicates that Nimesulide may increase the risk of gastrointestinal bleeding when taken alongside certain medications used for mental health, such as selective serotonin reuptake inhibitors (SSRIs).


Q: What does the term 'contraindication' mean for Nexen?

A: The term 'contraindication' means that the drug should not be used by a patient if they have one of the specific conditions or circumstances listed in the official label. Using the drug under these circumstances carries an unacceptable level of risk.


Q: Why is Nexen not recommended for people with [Specific Organ] disease?

A: The medicine is contraindicated in patients with severe hepatic (liver) impairment and severe renal (kidney) impairment. This restriction is due to the drug's metabolism and the risk of exacerbating severe organ disease, as stated in regulatory documents.


Q: Is it normal to feel a bit dizzy or lightheaded when starting Nexen?

A: Dizziness and vertigo are listed as potential undesirable effects in the official drug label.

How should Nexen be stored and disposed of?

How to Store and Dispose of Nexen (Nimesulide)

Nexen must be stored according to regulatory requirements to maintain its stability and effectiveness, focusing on environmental control and secure handling.

Storage Requirements

Condition Requirement
Temperature Limit Do not store the medicine above 30 C.
Environmental Protection Store in a dry, cool place and protected from light.
Packaging Rule Keep the product in its original, tightly closed container and do not use after the expiry date.
Child Safety Store the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Nexen must not be released into the environment. Disposal should follow applicable local and national regulations. The product and its container must be disposed of via an approved pharmaceutical waste disposal plant or authorized facility.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nexen found in:

A-Z Index: